Addressing Methodological Challenges with Clinical Trials of Psychotomimetic Agents

The National Institutes of Health (NIH) is offering a grant opportunity titled "Addressing Methodological Challenges with Clinical Trials of Psychotomimetic Agents," aimed at soliciting research applications that tackle the methodological issues associated with clinical trials involving psychotomimetic agents (PMAs). The focus of this initiative is to enhance the understanding of the therapeutic effects of PMAs, such as psilocybin and MDMA, which have shown potential benefits for mental health disorders like depression and anxiety, thereby increasing confidence in clinical trial outcomes. The estimated total program funding is $5 million, with approximately five awards anticipated, and interested applicants are encouraged to engage with the FDA prior to submission to ensure compliance with regulatory requirements. For further inquiries, potential applicants can contact Jonathan Sabbagh, Ph.D., at jonathan.sabbagh@nih.gov or by phone at 301-793-3534. The synopsis is expected to be posted on September 3, 2025, with applications closing on November 3, 2025, and awards anticipated by July 1, 2026.